Weight managementPeptide · Vial
Retatrutide
Weight management and appetite research.
$42.10USD · shipping confirmed separately
For laboratory research only. Not for human or animal consumption.
Product information
This material is informational and is not medical advice or an instruction for human use.Description
Retatrutide (LY3437943) is a triple receptor agonist studied for metabolic regulation and weight-management pathways.
How it works
- Activates GLP-1, GIP and glucagon receptors involved in appetite, insulin sensitivity and energy expenditure.
- Research also examines reward signalling, lipid markers and broader cardiometabolic effects.
Research outlook
Studies are exploring obesity, metabolic plateaus, fatty-liver disease and changes in food-related behaviour.
Research regimen
- Owner-supplied research reference: 0.5–2 mg once weekly, with gradual titration at four-week intervals.
Risks
- Gastrointestinal effects, fatigue and altered gastric motility may occur.
- The source notes contraindications relating to MTC, MEN 2, eating disorders and pregnancy.
Research
Phase II/III research examines triple-agonist efficacy, liver-fat outcomes and daily energy expenditure.